Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Virgin Galactic Holdings, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Virgin Galactic Holdings, Inc. trades at $2.6 (market cap $330.34M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 13.6× Virgin Galactic Holdings, Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | SPCE | |
|---|---|---|
Market Cap | $4.49B | $330.34M |
Sector | Health | Industrials |
52-Week High | $28.06 | $7.52 |
52-Week Low | $20.06 | $2.17 |
Enterprise Value | $3.69B | $430.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Virgin Galactic (SPCE) trades at $2.57, down 4.81% today, reflecting persistent bearish technical signals and weak fundamentals. The company continues to report significant losses, with a net income margin of -19,781.3% in 2025 and negative cash flow from operations. Recent news highlights volatility tied to SpaceX IPO developments, with SPCE shares experiencing sharp swings. Analyst consensus is mixed, with 29% buy, 41% hold, and 29% sell ratings, indicating cautious sentiment amid ongoing financial challenges.
The outlook remains highly speculative, with investment opportunity hinging on future commercial spaceflight success, but risks are substantial. High cash burn, lack of profitability, and intense competition threaten shareholder value. Without near-term revenue growth or path to profitability, the stock faces significant downside risk despite trading near historical lows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
